Merck & Co., Inc. is aiming to take new approaches to tackle Alzheimer’s disease through a partnership with Cerevance Inc. worth $25m upfront.
The partners will use Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology to identify novel targets for Alzheimer's. The...








